Chronic Lymphocytic Leukaemia (CLL) patients commonly develop resistance to gold-standard?therapy (the?irreversible Bruton’s Tyrosine Kinase [BTK] inhibitor,?ibrutinib)?due to a?genetic mutation. ?
Redx’s new candidate is?a reversible BTK inhibitor and could target?resistant CLL?and other blood cancers.
Could be a significant step in the potential advancement of CLL treatment.
— db (@3SixtyPharma) May 25, 2016